22
Participants
Start Date
January 3, 2024
Primary Completion Date
May 30, 2024
Study Completion Date
May 30, 2024
Placebo
Placebo-matching Avenciguat
Avenciguat
1 millligram (mg), 2 mg, or 3 mg film-coated tablet
AKH - Medical University of Vienna, Vienna
Soon Chun Hyang University Hospital Bucheon, Bucheon-si, Gyeonggi-do
Hospital Ramón y Cajal, Madrid
HOP Rangueil, Toulouse
Universitätsklinikum Münster, Münster
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz
California Liver Research Institute, Pasadena
HOP Beaujon, Clichy
Inland Empire Clinical Trials, LLC, Rialto
Beijing Friendship Hospital, Beijing
"Regional Institute of Gastroenterology Hepatology Prof. Dr. O. Fodor", Cluj-Napoca
NanFang Hosptial, Guangzhou
Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal
Shin-yurigaoka General Hospital, Kanagawa, Kawasaki
Hospital Vall d'Hebron, Barcelona
Lead Sponsor
Boehringer Ingelheim
INDUSTRY